Search

Delorazepam

It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.

DPI-221

DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

Darapladib

GFT14

) and on other risk factors such as hypertension or diabetes. … GFT14 is a new class of medicaction for treatment of cardiometabolic disease.

FS-1502

FS-1502 is an antibody-drug conjugate consisting of an anti-HER2 antibody, linker, and Monomethylauristatin F.

Bimoclomol

Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.

CHGN111

Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

TT 173

TT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental

LErafAON

Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.